Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.14B P/E 22.67 EPS this Y -11.50% Ern Qtrly Grth -
Income 42.14M Forward P/E 15.43 EPS next Y 16.00% 50D Avg Chg -7.00%
Sales 133.48M PEG 0.92 EPS past 5Y 11.78% 200D Avg Chg -6.00%
Dividend N/A Price/Book 1.76 EPS next 5Y 20.00% 52W High Chg -23.00%
Recommedations 2.00 Quick Ratio 14.31 Shares Outstanding 18.27M 52W Low Chg 39.00%
Insider Own 1.95% ROA 0.61% Shares Float 17.89M Beta 0.91
Inst Own 98.10% ROE 5.85% Shares Shorted/Prior 0.98M/1.06M Price 66.21
Gross Margin 75.03% Profit Margin 31.57% Avg. Volume 97,087 Target Price 124.00
Oper. Margin 17.80% Earnings Date Nov 6 Volume 54,918 Change -0.73%
About Ligand Pharmaceuticals Incorpor

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Incorpor News
11/16/24 Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
11/14/24 Ligand to Present at Stifel 2024 Healthcare Conference
11/11/24 LGND: 3Q Sales Surprise to the Upside
11/09/24 Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
11/08/24 Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price
11/08/24 Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
11/07/24 Ligand: Q3 Earnings Snapshot
11/07/24 Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
11/01/24 Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
10/23/24 Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
10/17/24 Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
10/09/24 Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
10/09/24 LGND: Initiating Coverage – A Prince Among Royalty
09/25/24 Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum?
09/06/24 Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
08/27/24 Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...
08/20/24 Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024
08/09/24 Insider Buying: CEO Todd Davis Acquires Shares of Ligand Pharmaceuticals Inc (LGND)
08/08/24 Ligand Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
LGND Chatroom

User Image SchroederO Posted - 3 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $BLTE $LGND

User Image NVDAMillionaire Posted - 3 days ago

$LGND Ligand Pharmaceuticals (LGND): Pioneering Innovative Strategies in the Biopharmaceutical Landscape https://beyondspx.com/article/ligand-pharmaceuticals-a-diversified-biopharmaceutical-powerhouse-delivering-consistent-growth

User Image Doozio Posted - 4 days ago

$xbi n all YO gotta do is wUtch how $lgnd ary it can get INTA 🧠⏰♾️

User Image docBNM Posted - 6 days ago

$LGND AGEN investment isn't looking so hot. Wonder what LGND saw that made them pull the trigger ? Or... what do they know that the stock mkt doesn't ???

User Image Biotech2424 Posted - 1 week ago

$CHRS Worth at least $4.00 $SMMT $LGND $PYXS

User Image FannyPackin Posted - 1 week ago

$LGND hit that 125-130 already, will take Lil time to get through there.. next leg early 2025 to 160 looks likely..

User Image IN0V8 Posted - 1 week ago

$LGND Opportunity Barclays raises target price to $150 from $125

User Image Doozio Posted - 2 weeks ago

How can it be a Thursday 🐑 suck in if they just started CHSN all da PHAT setups in da FUTUre of 🧠⏰ wen “they” said it wud be $lgnd ary INTA 🧠⏰♾️

User Image MichaelMantion Posted - 2 weeks ago

$LGND I think it can go up a little more.

User Image DonCorleone77 Posted - 2 weeks ago

$LGND Ligand raises FY24 EPS view to $5.50-$5.70, consensus $5.39 Ligand is increasing its 2024 full year financial guidance previously outlined in July. The company now expects total revenue of $160 million to $165 million, previously $140 million to $157 million, and is raising core adjusted earnings per diluted share to $5.50 to $5.70, previously $5.00 to $5.50. Royalties are expected to be $105 million to $108 million, previously $100 million to $105 million, sales of Captisol of $27 million to $29 million, previously $25 million to $27 million, and contract revenue of $28 million, previously $15 million to $25 million . This guidance excludes the $60 million realized gain from short-term investments on the sale of Viking Therapeutics stock. Consensus for FY24 revenue is $156.38M.

User Image DonCorleone77 Posted - 2 weeks ago

$LGND Ligand reports Q3 EPS $1.84, consensus $1.35 Reports Q3 revenue $51.81M, consensus $40.65M."We just had one of the best quarters of performance in the history of Ligand. This success is due to the ongoing strength of our growing portfolio of commercial-stage programs, and we are pleased to announce an increase in guidance for the second time this year," said Todd Davis, CEO of Ligand. "This quarter, we had several key portfolio events, including the successful commercial launches of Ohtuvayre(TM) and CAPVAXIVE(TM). as well as the full FDA approval of FILSPARI(R). We believe each of these products, along with our recently acquired QARZIBA(R), will be key drivers of revenue growth for Ligand in the coming years."

User Image Doozio Posted - 2 weeks ago

They started CHSN NOW in da FUTUre of 🧠⏰ n it shud get $lgnd ary NEXN in 🧠⏰♾️

User Image _Zoie_Ramirez_ Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $BLTE $LGND

User Image Estimize Posted - 2 weeks ago

Wall St is expecting 1.35 EPS for $LGND Q3 [Reporting 11/07 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co

User Image swingingtech Posted - 10/29/24

$LGND $ABNB $RMBS https://wallstreetwaves.com/significant-tuesday-options-trading-highlights-lgnd-abnb-rmbs/

User Image tyogs Posted - 10/25/24

$LGND LGND is flag polling. Huge gains ahead

User Image Doozio Posted - 10/24/24

So many $phat setups 🐑 ain’t even started or done CHSN yet in XBI IWM. “They” did say it wud be $lgnd ary during 🧠⏰♾️

User Image Doozio Posted - 1 month ago

“They” did say it was gonna become $lgnd ary once $xbi n $iwm got in $rytm during 🧠⏰♾️

User Image WeeklyTrader Posted - 1 month ago

Bulls are in control! $LGND None RSI: 53.46% 50-day MA: $102.2 200-day MA: $85.6

User Image Finanz Posted - 1 month ago

$LGND Zacks initiated coverage https://scr.zacks.com/news/news-details/2024/LGND-Initiating-Coverage--A-Prince-Among-Royalty-article/default.aspx

User Image WeeklyTrader Posted - 1 month ago

Feeling bullish? Grab a CALL on $LGND at strike None before it’s too late! RSI: 52.32% 50-day MA: $102.13 200-day MA: $85.45

User Image Stoxpo Posted - 1 month ago

Ligand Pharmaceuticals: A Diversified Biotech Powerhouse Poised for Growth https://stoxpo.com/index.php/2024/10/03/ligand-pharmaceuticals-a-diversified-biotech-powerhouse-poised-for-growth/ $LGND $QQQ

User Image Doozio Posted - 09/26/24

$xbi chop chop huckleberries da FUTUre of 🧠⏰ is NOW gonna be $lgnd ary during 🧠⏰♾️

User Image insiderbuyingselling Posted - 09/26/24

$LGND new insider selling: 2000 shares. http://insiderbuyingselling.com/?t=LGND

User Image insiderbuyingselling Posted - 09/25/24

$LGND new insider selling: 1275 shares. http://insiderbuyingselling.com/?t=LGND

User Image Doozio Posted - 2 months ago

$EWTX n they did! Bahhht who gives a fook all da macro jabronis been SPOT. Only faatch 💣s shud kill 🧠⏰ from here. Scrabble $entx while YO at it CUZ it gonna be $lgnd ary during 🧠⏰♾️

User Image Doozio Posted - 2 months ago

$xbi since 2012 wen it went $ pattern to begin this secular 🧠⏰ cycle. Then it topped feb of 2021 to begin the rolling bear market that crushed Jabroni’s in 2022 until a new 🧠 DAWN was born after a July MNDY Thursday 🐑 bahhtom in 2022 as 👁️ $spy indexes followed the bahhhtoms on a Thursday 🐑 low Oct of 2022. A 🧠👀 became 🧠⏰ in Oct/nov of 2023 as XBI IWM final lows were put in. This is 2020FOUR n it’s gonna $lgnd ary during 🧠⏰♾️. All yo gotta do is wUtch. Bums.

User Image Doozio Posted - 2 months ago

$lgnd ary 💩 happens with yo huckleberries in 🧠⏰

User Image FannyPackin Posted - 2 months ago

$LGND 125-130 seems likely, monthly/quarterly look great.. ~160 next year if can get through 130.. no position(yet)..

User Image briefingcom Posted - 2 months ago

$LGND: Ligand Pharma announces that its partner Travere Therapeutics ($TVTX) has received full approval from the U.S. FDA for FILSPARI to slow kidney function decline in adults with primary IgAN who are at risk of disease progression https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240906092138LGND&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Analyst Ratings
Benchmark Buy Aug 12, 24
RBC Capital Outperform Aug 12, 24
HC Wainwright & Co. Buy Aug 8, 24
RBC Capital Outperform Aug 7, 24
RBC Capital Outperform Jul 30, 24
Craig-Hallum Buy Jul 9, 24
HC Wainwright & Co. Buy Jul 8, 24
Benchmark Buy Jun 28, 24
HC Wainwright & Co. Buy Jun 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Davis Todd C CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 22 Buy 59.3822 4,000 237,529 73,090 09/25/23
KOZARICH JOHN W Director Director May 16 Sell 77.2009 4,444 343,081 38,488 05/18/23
KOZARICH JOHN W Director Director May 08 Sell 76.8 6,408 492,134 42,213 05/10/23
KOZARICH JOHN W Director Director May 08 Option 18.82 6,408 120,599 48,621 05/10/23
Reardon Andrew See Remarks See Remarks Mar 24 Sell 69.9243 300 20,977 16,308 03/28/23
HIGGINS JOHN L Director Director Dec 16 Sell 61.8657 10,000 618,657 422,984 12/20/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Sep 16 Sell 88.06 1,000 88,060 366,180 09/22/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Sep 15 Sell 89.68 5,000 448,400 364,180 09/16/22
FOEHR MATTHEW W President and COO President and COO May 13 Buy 82.7638 2,500 206,910 173,354 05/13/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer May 09 Option 21.92 8,000 175,360 348,593 05/10/22
KOZARICH JOHN W Director Director May 13 Option 10.12 4,835 48,930 34,543 05/13/21
Davis Todd C Director Director Feb 12 Option 195.91 2,474 484,681 50,152 02/12/21
Davis Todd C Director Director Feb 12 Sell 213.14 5,083 1,083,391 47,678 02/12/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Feb 09 Option 12.26 114,666 1,405,805 346,030 02/09/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Feb 09 Sell 203.4 54,666 11,119,064 286,030 02/09/21
Berkman Charles S SVP, Gen. Counsel &.. SVP, Gen. Counsel & Secretary Feb 05 Sell 178.5 18,097 3,230,314 28,906 02/05/21
FOEHR MATTHEW W President and COO President and COO Feb 05 Option 48.17 45,547 2,193,999 212,745 02/05/21
FOEHR MATTHEW W President and COO President and COO Feb 05 Sell 176.86 44,547 7,878,582 168,198 02/05/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Jan 27 Option 16.95 120,000 2,034,000 273,422 01/27/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Jan 27 Sell 170.5 90,000 15,345,000 243,422 01/27/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Dec 09 Option 10.05 14,657 147,303 236,770 12/09/20
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Nov 10 Option 10.05 20,000 201,000 224,571 11/10/20